secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2024-04-16T23:59:59+00:00
Accession:  0001628280-24-016281
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn appoints Kristian Humer as CFO; notes upcoming pipeline milestones for 2024
--------------------------------------------------------------------------------

- Kristian Humer appointed CFO effective April 16, replacing interim CFO Stephen DiPalma.
- Compensation: $475k base salary, 40% target bonus, $87k signing bonus, 275k-share option award.
- Humer brings 14+ years life science financial strategy; previously CFO/CBO at Viridian Therapeutics.
- Lead program FHD-286 AML data expected H2 2024; FHD-909 (with Lilly) IND filing on track Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828024016281/0001628280-24-016281-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828024016281/fhtx-20240416.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-016281

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer